File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A controlled trial of Bestatin in hydatidiform mole

TitleA controlled trial of Bestatin in hydatidiform mole
Authors
Issue Date1990
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00262/index.htm
Citation
Cancer Immunology Immunotherapy, 1990, v. 31 n. 3, p. 187-190 How to Cite?
AbstractA prospective randomized controlled trial was conducted to study whether Bestatin, an immunomodifier, can reduce the incidence of persistent gestational trophoblastic disease in patients with hydatidiform mole. A group of 21 patients (Bestatin group) received 30 mg Bestatin daily after evacuation of the hydatidiform mole. A second group of 23 patients (control group) did not receive any drug. Blood was taken for white cell counts, differential counts, lymphocyte subset counts (CD2+, CD4+, CD8+ and B cells) and natural killer cell activity before evacuation of the hydatidiform moles. The tests were repeated every 4 weeks after evacuation until the serum β subunit of human chorionic gonadotropin (βhCG) had returned to normal or until the patient had to receive chemotherapy because of persistent gestational trophoblastic disease. There was no significant difference in the age of the patients, the pre-evacuation serum βhCG, or the gestational age between the two groups. Chemotherapy was needed by 6 patients in the Bestatin group (28.6%) and 3 patients in the control group (13%) because of persistent gestational trophoblastic disease. There was no significant difference in any of the immunological parameters between the two groups before or after evacuation. We conclude that Bestatin at this dosage does not improve the immunological functions or clinical outcome in patients with hydatidiform mole.
Persistent Identifierhttp://hdl.handle.net/10722/173167
ISSN
2015 Impact Factor: 4.846
2015 SCImago Journal Rankings: 2.066
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHo, PCen_US
dc.contributor.authorWong, LCen_US
dc.contributor.authorLawton, JWMen_US
dc.contributor.authorMa, HKen_US
dc.date.accessioned2012-10-30T06:28:18Z-
dc.date.available2012-10-30T06:28:18Z-
dc.date.issued1990en_US
dc.identifier.citationCancer Immunology Immunotherapy, 1990, v. 31 n. 3, p. 187-190en_US
dc.identifier.issn0340-7004en_US
dc.identifier.urihttp://hdl.handle.net/10722/173167-
dc.description.abstractA prospective randomized controlled trial was conducted to study whether Bestatin, an immunomodifier, can reduce the incidence of persistent gestational trophoblastic disease in patients with hydatidiform mole. A group of 21 patients (Bestatin group) received 30 mg Bestatin daily after evacuation of the hydatidiform mole. A second group of 23 patients (control group) did not receive any drug. Blood was taken for white cell counts, differential counts, lymphocyte subset counts (CD2+, CD4+, CD8+ and B cells) and natural killer cell activity before evacuation of the hydatidiform moles. The tests were repeated every 4 weeks after evacuation until the serum β subunit of human chorionic gonadotropin (βhCG) had returned to normal or until the patient had to receive chemotherapy because of persistent gestational trophoblastic disease. There was no significant difference in the age of the patients, the pre-evacuation serum βhCG, or the gestational age between the two groups. Chemotherapy was needed by 6 patients in the Bestatin group (28.6%) and 3 patients in the control group (13%) because of persistent gestational trophoblastic disease. There was no significant difference in any of the immunological parameters between the two groups before or after evacuation. We conclude that Bestatin at this dosage does not improve the immunological functions or clinical outcome in patients with hydatidiform mole.en_US
dc.languageengen_US
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00262/index.htmen_US
dc.relation.ispartofCancer Immunology Immunotherapyen_US
dc.subject.meshAdjuvants, Immunologic - Therapeutic Useen_US
dc.subject.meshAdulten_US
dc.subject.meshB-Lymphocytesen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHydatidiform Mole - Therapyen_US
dc.subject.meshKiller Cells, Natural - Immunologyen_US
dc.subject.meshLeucine - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshLeukocyte Counten_US
dc.subject.meshPregnancyen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshT-Lymphocytesen_US
dc.titleA controlled trial of Bestatin in hydatidiform moleen_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF01744735en_US
dc.identifier.pmid2186854-
dc.identifier.scopuseid_2-s2.0-0025332326en_US
dc.identifier.volume31en_US
dc.identifier.issue3en_US
dc.identifier.spage187en_US
dc.identifier.epage190en_US
dc.identifier.isiWOS:A1990DB92500010-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US
dc.identifier.scopusauthoridWong, LC=7402092003en_US
dc.identifier.scopusauthoridLawton, JWM=7102180792en_US
dc.identifier.scopusauthoridMa, HK=7403095603en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats